Dr. Kremer reflects on the CORRONA enterprise: “I never set out to do all this. It was just one of those classic situations where one thing led to another: You start collaborating with really good people, your horizons expand, and you recognize that some of the dots can be connected in various domains of our discipline.” Dr. Greenberg echoes that idea: “There is a need for complementary sources of drug safety data for long-term pharmacovigilance,” he notes, “and the potential for new registries, nested clinical trials [such as the CERTAIN or Treat-to-Target (T2T) substudies] is tremendous.”
It looks like the registry is on track to capitalize on its potential. Besides the starts of the spondylarthropathy and gout registries, plans are also in the works for a lupus registry sometime in the next year. “We’ve done good things,” says Dr. Kremer, “but the glass is half full—we still have an awful lot of hard work to do.”
Gretchen Henkel is writing the “Metrics in Rheumatology” series.
Timeline
2001 –CORRONA established
2001 –First patient enrolled in RA registry
2005 –First patient enrolled to RA Pharmacogenetics substudy
2010 –First patient enrolled CERTAIN comparative biomarker substudy
2010 –CORRONA International established
2011 –CORRONA Clinical Trials corporation established
2011 –First patient enrolled in the CORRONA Treat-to-Target Trial
2011 –First patient enrolled for the CORRONA International registry
2012 –First patient enrolled in CORRONA gout registry
2012 –CORRONA International expanded to include South Africa and Australia
2012 –First patient enrolled in CORRONA SpA registry
